Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2223541 | 0.87 | KMT2A (0.64) | GSK3BKMT2AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL15947022 | 0.85 | RORC (0.55) | RORCKMT2AMEN1CYP3A4MAPK1 | |
| SCHEMBL27623443 | 0.84 | RORC (0.54) | RORCKMT2AMEN1CYP3A4MAPK1 | |
| SCHEMBL6568119 | 0.84 | KDM4E (0.58) | RORCKMT2AMEN1CYP3A4MAPK1 | |
| SCHEMBL12518458 | 0.83 | HSD17B10 (0.51) | RORCKMT2AMEN1CYP3A4MAPK1 | |
| SCHEMBL1428822 | 0.82 | L3MBTL1 (0.58) | GSK3BKMT2AMEN1CYP3A4MAPK1 | |
| SCHEMBL10558632 | 0.81 | HSD17B10 (0.58) | RORCKMT2AMEN1CYP3A4MAPK1 | |
| SCHEMBL10953243 | 0.81 | HSD17B10 (0.62) | RORCKMT2AMEN1CYP3A4MAPK1 | |
| SCHEMBL7090078 | 0.81 | GSK3B (0.56) | GSK3BRORCKMT2AMEN1CYP3A4 | |
| SCHEMBL31415407 | 0.81 | GSK3B (0.56) | GSK3BRORCKMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296754-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-03-29 | — | — | US | disclosed |
| US-9296754-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-03-29 | — | — | US | disclosed |
| US-9296754-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-03-29 | — | — | US | disclosed |
| US-20160045505-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| US-20160045505-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| WO-2014151784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275119-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275119-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275119-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-1745041-B1 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | GENENTECH INC (US) | 2012-06-20 | — | — | EP | disclosed |
| EP-1745041-B1 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | GENENTECH INC (US) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011085261-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1745041-A2 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | Genentech, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006078283-A2 | QUINOXALINE INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | SHH, NR4A2, NR4A3 | GSK3B 2470/4885RORC 172/4885KMT2A 1167/4885 |
| US-20140275119-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | GSK3B 140/4885RORC 42/4885KMT2A 2625/4885 |
| US-20160045505-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TUBA1C, TBCA | GSK3B 152/4885RORC 66/4885KMT2A 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.